Borenius advised DNB Carnegie, as the sole global coordinator, on Bioretec’s rights issue of EUR 12.9 million

We advised DNB Carnegie Investment Bank AB, Finland Branch, as the sole global coordinator, on Bioretec Ltd’s rights issue of EUR 12.9 million. In the rights issue, Bioretec offered new shares for subscription to its existing shareholders in proportion to their pre-emptive subscription rights. Bioretec published an 11-page exemption document under the exemption framework made available by the EU Listing Act. In connection with the transaction, Bioretec’s largest shareholder was granted a permanent exemption from the obligation to launch a mandatory public takeover bid.

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopaedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopaedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. Bioretec’s shares are listed on Nasdaq First North Growth Market Finland.